Related Experiment Video

Updated: Jun 25, 2026

Understanding the Development of Compensatory Pathways in a Mutant Malaria Parasite Harbouring Hypomorphic Allele of Plant-Like Kinases
09:13

Understanding the Development of Compensatory Pathways in a Mutant Malaria Parasite Harbouring Hypomorphic Allele of Plant-Like Kinases

Published on: November 22, 2024

Recombinant plasmepsin 1 from the human malaria parasite plasmodium falciparum: enzymatic characterization, active

Peng Liu1, Melissa R Marzahn, Arthur H Robbins

  • 1Department of Biochemistry and Molecular Biology, University of Florida, College of Medicine, Gainesville, Florida 32610-0245, USA.

Biochemistry
|March 11, 2009
PubMed

Insights

Researchers developed a new inhibitor targeting Plasmodium falciparum plasmepsin 1 (PfPM1), a key enzyme in malaria parasites. This inhibitor shows selectivity over human cathepsin D, offering a potential therapeutic strategy against malaria.

Area of Science:

  • Biochemistry and Molecular Biology
  • Parasitology
  • Drug Discovery

Background:

  • Plasmepsins are aspartic proteases essential for the growth of the malaria parasite Plasmodium falciparum.
  • Targeting plasmepsins is a promising strategy for developing novel antimalarial drugs.

Purpose of the Study:

  • To generate and characterize a recombinant form of truncated proplasmepsin 1 (proPfPM1) from Plasmodium falciparum.
  • To investigate the substrate specificity of mature PfPM1 and design selective inhibitors.
  • To determine the structural basis for inhibitor binding.

Main Methods:

  • Overexpression of mutated proPfPM1 (proPfPM1 K110pN) in Escherichia coli.
  • In vitro auto-maturation and determination of optimal catalytic pH.
  • Peptide library screening to explore S3-S3' subsite preferences.
  • Design and synthesis of peptidomimetic inhibitors.
  • X-ray crystallography of the PfPM2-inhibitor complex.
  • Homology modeling of PfPM1 and PfPM4.

Main Results:

  • Recombinant mature PfPM1 exhibited comparable binding affinity to substrates and inhibitors as the native form.
  • A peptidomimetic inhibitor (compound 1) demonstrated 5-fold selectivity for PfPM1 over human cathepsin D.
  • The 2.8 Å crystal structure of the PfPM2-compound 1 complex provided insights into inhibitor binding.

Conclusions:

  • Recombinant PfPM1 can be effectively produced and characterized.
  • The designed peptidomimetic inhibitor shows potential as a selective antimalarial agent.
  • Structural data aids in the rational design of improved plasmepsin inhibitors.

More Related Videos

CRISPR/Cas9 Gene Editing to Make Conditional Mutants of Human Malaria Parasite P. falciparum09:25

CRISPR/Cas9 Gene Editing to Make Conditional Mutants of Human Malaria Parasite P. falciparum

Published on: September 18, 2018

Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds07:14

Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds

Published on: July 11, 2025

Related Concept Videos

Malaria01:29

Malaria

Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
Conservative Site-specific Recombination and Phase Variation02:53

Conservative Site-specific Recombination and Phase Variation

Because the DNA segments are cut and reorganized in a direction-specific manner, site-specific recombination has emerged as an efficient genetic engineering technique. Flippase and Cyclization recombinases or Flp and Cre, respectively, are two members of the tyrosine recombinase family derived from bacteriophages, that are used to mediate site-specific DNA insertions, deletions, and targeted expression of proteins in mammalian cell lines.
The recognition sites for Cre recombinase called LoxP...